Conservative treatment of diffuse uterine leiomyomatosis

Fertil Steril. 2004 Aug;82(2):450-3. doi: 10.1016/j.fertnstert.2004.01.029.

Abstract

Objective: To describe the conservative treatment of diffuse uterine leiomyomatosis.

Design: Descriptive study.

Setting: Tertiary care centers.

Patient(s): Three premenopausal women with diffuse uterine leiomyomatosis associated to persistent menorrhagia, two with desire of becoming pregnant and one with desire of preservation of the uterus.

Intervention(s): Preoperative ultrasound showed symmetrically enlarged uteri with innumerable, poorly defined and small-sized (0.5-3 cm) myomas involving all the myometrium. An "extreme" myomectomy was performed in two cases, including the removal of a large portion of corporal myometrium. One patient was treated only medically with GnRH analogues (GnRH-a).

Main outcome measure(s): Menstrual pattern and, when applicable, ability to conceive and pregnancy outcome.

Result(s): Regular menses were restored in both patients who underwent surgery: one had no pregnancy desire and the other was not able to conceive after two IVF-ETs. The patient treated with GnRH-a conceived spontaneously as soon as medical treatment was discontinued; at 34 gestational weeks, an emergency cesarean section followed by hysterectomy was performed for vaginal bleeding and a healthy 2,400-g baby was born.

Conclusion(s): Our experience supports the idea that a conservative approach to uterine leiomyomatosis may result in restoration of normal cycles and eventually in the birth of a viable fetus.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Buserelin / therapeutic use
  • Female
  • Gonadotropin-Releasing Hormone / analogs & derivatives
  • Humans
  • Laparotomy
  • Leiomyoma / surgery
  • Leiomyoma / therapy*
  • Menorrhagia / etiology
  • Pregnancy
  • Pregnancy Complications, Neoplastic / surgery
  • Pregnancy Complications, Neoplastic / therapy*
  • Uterine Neoplasms / surgery
  • Uterine Neoplasms / therapy*

Substances

  • Gonadotropin-Releasing Hormone
  • Buserelin